Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
February 09 2023 - 7:00AM
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology
company dedicated to discovering and developing transformative
treatments to restore and improve hearing and balance, today
announced that it will present findings from its drug discovery and
development programs at the 46th Annual MidWinter Meeting of the
Association for Research in Otolaryngology (ARO), being held in
Orlando, Florida February 11–15, 2023.
The Company will present new data on
its lead investigational gene therapy product candidate, DB-OTO, as
well as new data across its gene therapy pipeline. Decibel will
also present additional data from the interim analysis of the Phase
1b clinical trial of DB-020 in patients receiving cisplatin
chemotherapy.
Podium Presentations
Podium 1 | Precise Targeting
of GJB2 Cells Results in Safe and Efficacious Gene Therapy in a
Rodent Model of Hearing Loss Due to GJB2
DeficiencyPresenter: Kathryn Ellis, Ph.D.Session Title:
Gene Therapy Date & Time: Saturday, February 11, 2:00 – 4:00
p.m. ET
Podium 26 | Development of
DB-020, a Locally Administered Product for Protection Against
Cisplatin-Induced OtotoxicityPresenter: John LeeSession
Title: Cisplatin OtotoxicityDate & Time: Tuesday, February 14,
10:30 a.m. – 12:30 p.m. ET
Poster Presentations
SU83 | Development of a
Platform for Parallel Functional Evaluation of Cell Type Specific
Synthetic Promoters for Gene Therapy
SU84 | Dual Vector Gene
Therapy Approaches for STRC-Related Hearing Loss
MO83 | Nonclinical
Pharmacology, Biodistribution, and Safety Studies Supporting the
Clinical Development of DB-OTO (AAV1-Myo15-hOTOFv5) for Hearing
Loss Due to Genetic Otoferlin Protein Deficiency
TU83 | Development of a
Utricle Culture System for Exploring Dual AAV-Mediated Expression
Kinetics of Human Otoferlin
TU232 | Advancing
Bioinformatically Informed Targets to Achieve In
Vivo Vestibular Regeneration
About Decibel TherapeuticsDecibel Therapeutics
is a clinical-stage biotechnology company dedicated to discovering
and developing transformative treatments to restore and
improve hearing and balance, one of the largest areas of unmet
need in medicine. Decibel has built a proprietary platform that
integrates single-cell genomics and bioinformatic analyses,
precision gene therapy technologies and expertise in inner ear
biology. Decibel is leveraging its platform to advance gene
therapies designed to selectively replace genes for
the treatment of congenital, monogenic hearing loss and to
regenerate inner ear hair cells for the treatment of acquired
hearing and balance disorders. Decibel’s pipeline, including its
lead gene therapy product candidate, DB-OTO, to treat
congenital, monogenic hearing loss, is designed to deliver on our
vision of creating a world of connection for people with
hearing and balance disorders. For more information about
Decibel Therapeutics, please visit www.decibeltx.com or follow us
on Twitter.
Investor Contact:Julie SeidelStern IR,
Inc.212-362-1200Julie.seidel@sternir.comMedia
Contact:Chris RaileyTen Bridge
Communications617-834-0936chris@tenbridgecommunications.com
Decibel Therapeutics (NASDAQ:DBTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Decibel Therapeutics (NASDAQ:DBTX)
Historical Stock Chart
From Jul 2023 to Jul 2024